Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Closing snapshot: lower for longer blues, retail hymn

Thu, 17th Sep 2020 16:59

* European shares open lower: STOXX down 0.6%

* Fed fails to cheer investors

* BoE briefed on negative rates

* Unibail-Rodamco drops on capital strengthening move
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

CLOSING SNAPSHOT: LOWER FOR LONGER BLUES, RETAIL HYMN (1539 GMT)

The Fed-BoE combo didn't do much for European stocks today, particularly for banking stocks
which see no light at the end of the tunnel in terms of interest rate hikes and inflation.

The banking sector scored the worst performance with a 1.4% fall and at one point during the
session was back to lows not seen since May.

The STOXX 600 closes down 0.4% at about 372 points, right in the trading range it has been
stuck in since June.

Tech lost 0.8% but that's arguably not that bad given that the pressure currently piling on
the Nasdaq which, at the time of writing, was down 1.3%.

On the bright side, retail made it into positive territory thanks notably to the UK's Next
which raised its outlook and demonstrated yet again the unexpected resilience of some key
companies in the sector.

Because it's certainly not rosy for the industry just as a quick look at the shares of
shopping mall owner Unibail-Rodamco shows.

The real estate group fell 10% after announcing its plans to raise 3.5 billion euros to
shore up its balance sheet and cope with the fallout from the COVID-19 pandemic.

Anyhow, Retail is among the happy few sectors in the black (0.1%) year to date with Tech
(+8.5%), Chemicals (+5.2%) and Healthcare (+0.8%).

Here's a chart of European retail bouncing back to the black in 2020:

(Julien Ponthus)

*****

DEATH AND (CORPORATE) TAXES (1503)

Nothing is certain except death and taxes, that old sage Benjamin Franklin apparently said.
For one group though it's not always true -- multinationals who stand accused of exploiting a
multitude of loopholes to hand over as little as possible to the taxman.

For years, countries have also vied with each other to lure companies by cutting corporate
tax rates. Some have cut rate so far they are effectively tax havens; academics from the
Universities of Berkeley and Copenhagen calculate that in 2015, multinationals shifted $600
billion -- 40% of their overseas profits -- into such havens. The figure, five years on, will be
far higher.

But even if we leave out the havens, the fact remains that statutory corporate tax rates
have fallen steadily since 1980 - the Tax Foundation, a non-profit, calculates corporate tax
rates currently average 24% -- down from an admittedly high 40% in 1980.

Deutsche Bank analyst Jim Reid highlights this problem in a note, describing falling
corporate tax rates "the ultimate expression of inequality, as it's been a huge boost for
capital over labour." It may also be why huge budget deficit have become a near-permanent
feature in many countries, he suggests.

Now though, governments desperate for cash after COVID spending binges, will be eyeing up
the corporate cash piles, especially as ending profit-shifting and tax evasion will take time.

"As we try to pay for the cost of the pandemic, and de-globalisation slowly reduces the risk
of companies moving jurisdiction, the likelihood is that low corporate tax rates will come under
increasing scrutiny," Reid writes.

(Sujata Rao)

*****

FTSE 100: WITH A LITTLE HELP OF THE BOE (1147 GMT)

The FTSE 100 is currently the best performing blue chip index in Europe with a 0.4% dip at
the moment and it's got someone to thank for it: the BoE!

The pound took a big blow after the central bank said it had been briefed on how a negative
interest rate could be implemented effectively.

That led to a good old 'pound down, FTSE 100' kneejerk reaction as you can see below:

The policy statement was otherwise bang in line with expectations:

(Julien Ponthus)

*****

BANKS: "NO LIGHT AT THE END OF THE TUNNEL" (1043 GMT)

The Fed didn't exactly lift spirits in the banking universe which really needs to make its
peace with the 'lower for longer' state of play.

The sector in Europe touched a May low this morning, which says quite a lot about the total
inability of its shares to bounce back from the COVID-19 March crash.

Year-to-date, European banking stocks are down over 38% (yes that's the worst sector) and
only managed to recoup 11% after seeing their market value nearly halve in March.

With banks down 2% in morning trading, we asked Jerome Legras at Axiom Alternative
Investments what he made of the latest price action.

"There no light at the end of the tunnel, in terms of interest rates", he told us, noting
that the sector was still trapped in a downward trend.

Also, while earnings expectations have bottomed out for this year and next, there's still
angst out there we could have nasty surprises on COVID-19 triggered loan losses.

"Models are just that, models", Legras said, adding that forecasting the cost of risk in
this unprecedented pandemic was a tricky business indeed which made many investors
uncomfortable..

Anyhow, if you're wondering whether banks are a great value bet or a doomed value trap,
here's a decision tree from UBS which might help:

(Julien Ponthus and Danilo Masoni)

*****

FOOD DELIVERY: APPETITE FOR M&A (1012 GMT)

Delivery Hero shares are doing nicely morning after it announced a 230 million
euro acquisition that will boost its footprint in Latin America.

The deal is relatively small but highlights the industry's dealmaking potential, which looks
to be intact despite consolidation already driving growth in this tech-based sector for years.

"We welcome this move and have flagged several times in our research that M&A is just at the
beginning in the food delivery space with plenty of optionality," say JPMorgan analysts.

There's no certainty about which deal is coming next, but looking at this summer, a couple
of big transactions stand out. Uber agreed to Postmates for $2.65 billion in July, just
one month after Just Eat Takeaway sealed a $6 billion deal to buy U.S. peer GrubHub
.

(Danilo Masoni)

*****

TIGHT LENDING STANDARDS NO LONGER DOOMSDAY FOR HIGH YIELD BONDS (0955 GMT)

High-yield credit spreads have managed to tighten even as banks tighten their lending
standards, Goldman Sachs says in a research note.

That's in contrast to the 2001 and 2008-2009 recessions, where credit spreads widened as
lending standards tightened, the bank said.

While lending standards tighten, high-yield issuance in the public markets is on track for a
record year. Nearly $300 billion of debt issued this year is already higher than full year
issuance in every single year since 2014.

One might argue that the pace of issuance demonstrates firms are opting for the public debt
markets given restrictive lending standards. Goldman doesn't buy into that argument, since
credit spreads are tightening despite a heavy pace of issuance, which signals strong demand.

Had the opposite been the case, credit spreads would widen with the increase in issuance.

Goldman sees the disconnect between bank lending and public debt markets as a positive for
credit risk, as it means that companies will become less vulnerable to the impact of an
exogenous shock that could hit commercial banks, since they are relying on a wider range of
lenders.

And it's not only the public markets that offer companies an alternative to bank lending.
Assets under management by private debt vehicles - which finance firms unable or unwilling to
issue public debt - were up 200% since 2009 by the end of last year, Goldman said.

(Yoruk Bahceli)

*****

NO BUBBLE IN TECH? (0937 GMT)

The tech bubble dilemma has been the talk of town for months. At the beginning of September
the Nasdaq was at an all-time high but only three weeks later a sharp correction has wiped off
around 1,000 points from the tech-heavy U.S. index.

Software has been Credit Suisse's largest overweight for the last decade but now the Swiss
bank reduced the size of its overweight saying that "excess in tech is high" though "in most
instances not extreme."

Fund managers recently surveyed by BoFA sounded a bit more cautious. For them the "tech
bubble" is now the second biggest tail risk after COVID-19 second wave.

But valuation metrics would suggest we're still far from bubble territory, according to
Credit Suisse. Bubbles have re-rated to a P/E ratio of 45-72 times and the Nasdaq is currently
on 37 times, it says in a research note.

The Swiss bank still recommends being overweight because tech is defensive, cyclical into an
upturn, growth-oriented and will likely benefit from a weak dollar.

Even though it cut software to overweight from strong overweight it remains "very positive"
on Microsoft and SAP. It has a small overweight on semis and likes gaming
stocks.

Despite the broadly positive stance, Credit Suisse warns that a COVID-19 vaccine "could
cause a short-term reversal in some of the online trends and would help other sectors" such as
financials and leisure.

(Stefano Rebaudo)

*****

EUROPE AT THE OPEN: ALL DOWN BUT WITHIN RANGES (0717 GMT)

Europe is literally painted red this morning with the STOXX 600 and all sub-sectors
posting losses in early deals after the Fed failed to provide fresh reasons to cheer.

Autos, banks and miners are sliding over 2% while tech is down 1.6%.

Despite the undistinguished sell-off, main indexes aren't breaking any new ground, the STOXX
is just giving up two days of gains and it remains anchored within its recent trading range.

Top faller is shopping centres landlord Unibail-Rodamco down 8% after it announced
a 9.0 billion euro plan to strengthen its finances. IG Group and Next are among the few stocks
on the up after well-received trading updates.

Here's your snapshot:

(Danilo Masoni)

*****

ON OUR RADAR: CENTRAL BANKS, BALANCE SHEETS AND TECH TROUBLES (0637GMT)

Futures in Europe are pointing to falls of more than 1% as investors digest a number of
central bank meetings, starting from the Fed which failed to offer any new reason to cheer, and
fresh heavy falls in U.S. tech stocks.

Earlier this morning the BoJ kept monetary policy steady and slightly upgraded its view on
the economy, while later on the BoE is expected to signal that it is getting ready to pump yet
more stimulus into Britain's economy.

Euro STOXX 50 futures were last down 1.3% and FTSE 100 futures fell 1% following a tech-led
sell off on Wall Street overnight. Nasdaq futures were down nearly 2%.

On the corporate front a few companies are taking steps to strengthen their balance sheets.

Shopping centres landlord Unibail-Rodamco announced 9.0 billion euros plan to
strengthen its finances that includes a 3.5 billion capital increase along with curbs to cash
dividends and non-essential capex.

In the UK, Rolls-Royce said it continued to review funding options, including debt
and equity, to boost its balance sheet, while the world's largest holiday company
TUI is planning a share sale to raise up to 1 billion euros, according to people
close to the matter.

In more upbeat news, Delivery Hero shares could rise after news it will buy the
Latin American operations of Glovo for up to 230 million euros.

Next raised its profit outlook for the second time in two months as the British
clothing retailer reported strong recent trading.

Eyes also on Spanish banks with Caixabank and Bankia set to approve a
deal today that will create Spain's biggest domestic lender.

Meanwhile on the COVID-19 front, there are no signs of the global pandemic slowing
but more positively an Oxford University document said the adverse events that led
to a pause in trials evaluating AstraZeneca vaccine candidate may not have been
associated with the vaccine itself.

(Danilo Masoni)

*****

MORNING CALL: EUROPE SEEN LOWER POST-FED (0529 GMT)

European shares are expected to open lower this morning with futures on the Euro STOXX 500
falling almost 1% following losses on a tech-led sell-off at Wall Street overnight and after the
Federal Reserve took no new policy action.

The U.S. central bank kept interest rates pinned near zero and promised to keep them there
until inflation is on track to "moderately exceed" its 2% inflation target "for some time."

Over in Asia, MSCI's broadest index of Asia-Pacific shares outside Japan was
down 1.1%, running out of steam after five straight days of gains. Japan's Nikkei shed
0.6%.

(Danilo Masoni)

*****

More News
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more
6 Sep 2023 07:45

AstraZeneca working with FDA on finer details of Ultomiris treatment

(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).

Read more
4 Sep 2023 15:46

UK dividends calendar - next 7 days

Tuesday 5 September 
no events scheduled 
Wednesday 6 September 
no events scheduled 
Thursday 7 September 
Admiral Group PLCex-dividend payment date
Alpha Financial Markets Consulting PLCex-dividend payment date
Anglo-Eastern Plantations PLCex-dividend payment date
Assura PLCex-dividend payment date
Athelney Trust PLCex-dividend payment date
Baltic Classifieds Group PLCex-dividend payment date
Blackrock World Mining Trust PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
CT UK Capital & Income Investment Trust PLCex-dividend payment date
Derwent London PLCex-dividend payment date
Develop North PLCex-dividend payment date
DS Smith PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Greggs PLCex-dividend payment date
Harbour Energy PLCex-dividend payment date
Pollen Street PLCex-dividend payment date
Prudential PLCex-dividend payment date
Relx PLCdividend payment date
RM Infrastructure Income PLCex-dividend payment date
Serco Group PLCex-dividend payment date
Severfield PLCex-dividend payment date
VPC Specialty Lending Investments PLCex-dividend payment date
XP Power Ltdex-dividend payment date
Zotefoams PLCex-dividend payment date
Friday 8 September 
abrdn New Dawn Investment Trust PLCdividend payment date
Avon Protection PLCdividend payment date
Berkeley Group Holdings PLCdividend payment date
Chemring Group PLCdividend payment date
Ecofin US Renewables Infrastructure Trust PLCdividend payment date
iomart Group PLCdividend payment date
Keller Group PLCdividend payment date
Lookers PLCdividend payment date
Moneysupermarket.com Group PLCdividend payment date
Nichols PLCdividend payment date
Tritax EuroBox PLCdividend payment date
Tyman PLCdividend payment date
Monday 11 September 
AstraZeneca PLCdividend payment date
Games Workshop Group PLCdividend payment date
Rentokil Initial PLCdividend payment date
Residential Secure Income PLCdividend payment date
ThomasLloyd Energy Impact Trust PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.